Source: European Commission (video statements)
Due to the urgency, COVID-19 vaccines are being developed faster, but they will still meet the same high standards and only go on the market after proven safe for all. The European Medicines Agency has mobilised extra resources to constantly monitor any side effects and quickly act on potential risks while ensuring maximum transparency. The Agency has a Europe-wide database of reports and regularly exchanges information globally. Manufacturers are committed to do more tests based on new technologies and to send safety reports every month, instead of every six months. Member States are preparing equipment, infrastructure and logistics, training health workers and addressing citizens’ concerns.
Watch on the Audiovisual Portal of the European Commission: https://audiovisual.ec.europa.eu/en/video/I-200091
Subscribe to our channel: https://bit.ly/2X56Ju6
Follow us on:
Check our website: http://ec.europa.eu/